Alector Inc
Alector Inc (ALEC) Options Open Interest
ALEC options open interest is 3,571 contracts. The 2-week average daily volume is 182 contracts across the chain.
Read more
Monitoring ALEC open interest helps you see where real money is positioned on Alector Inc's options and which strikes are attracting the most commitment from traders. Alector Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor ALEC options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising ALEC options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Alector Inc to settle.
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where ALEC open interest is concentrated. Our scanner maps Alector Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Alector Inc's options open interest as the signal it is, not as an afterthought.
| 2.50 | 0.05 | 0.35 | 0.20 | 182% | +0.3873 | 1,794 |
| 2.00 | — | 1.00 | 1.00 | 534% | +0.7577 | 318 |
| 7.50 | — | 0.05 | 0.05 | 292% | +0.0940 | 91 |
| 0.50 | 0.90 | 1.90 | 1.40 | 52% | +1.0000 | 87 |
| 1.50 | — | 1.00 | 1.00 | 446% | +0.7910 | 36 |
| 1.50 | — | 0.15 | 0.15 | 172% | -0.2250 | 140 |
| 2.00 | — | 1.00 | 1.00 | 483% | -0.2653 | 71 |
| 0.50 | — | 0.05 | 0.05 | 398% | -0.0376 | 23 |
| 2.50 | — | 0.85 | 0.85 | 215% | -0.5630 | 13 |
| 1.00 | — | 0.05 | 0.05 | 211% | -0.0782 | 0 |
As of September 21, 2026
Follow the money
Track ALEC open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→